Hilco is delighted to present for sale a UK-based medical diagnostics business pioneering the use of salivary biomarkers to transform oral healthcare and its connection to wider systemic conditions (the “Company”). Backed by an Innovate UK funded machine learning and proprietary digital platform, the Company combines real-world clinical datasets with a commercial application across consumer, insurance and dental channels. With CE and CA-marked kits ready for market deployment, strong momentum from RUO testing among early adopters, and registration as a general IVD across the UK and Europe, this is a market-ready scalable opportunity in a category set for growth.
This is a rare opportunity to acquire a clinically grounded, IP-led diagnostics business with live commercial engagement, early user traction, and a scalable platform play into both dental and broader healthcare markets. For companies interested in adding an innovative oral care solution that brings strong synergies with an existing product and service portfolio, this would be an opportunity to gain more than 2 years in time to market.
Offers Invited
All expressions of interest and bids are to be directed to Hilco in writing. Please contact Hilco to gain access to a virtual data room for further information on signing a confidentiality agreement.
Hilco is acting as exclusive agent to the Company in connection with the proposed sale of some or all of the Company’s business and assets (or shares).
All sales are made strictly on an “as seen, where lying” basis. Only such right, title and interest (if any) as the Company may have in the assets will be transferred to a purchaser. No warranties, guarantees, or representations (express or implied) are provided by the Company or Hilco in respect of the assets or any information supplied. All parties must rely on their own enquiries and due diligence. Any information provided is for convenience only and has not been independently verified.
All offers are subject to the addition of VAT at the prevailing rate, where applicable. A non-refundable deposit equal to 20% of the agreed purchase price must be paid by the successful purchaser within 48 hours of offer acceptance. Payment of the deposit grants the purchaser the exclusive right to proceed with the acquisition of the relevant assets for a limited period and on the terms agreed. A Buyer’s Premium of 10% of the final purchase price is payable by the successful purchaser in addition to the agreed purchase price, is non-negotiable and is payable at the same time and in the same manner as the purchase price and forms a condition of sale.
Legal completion must occur within five (5) business days of offer acceptance, unless otherwise agreed in writing by the Company and Hilco. Failure to complete within this period may result in forfeiture of the deposit and termination of the transaction.
Associate Director
Manchester Office
